Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives

CD30 is overexpressed in several lymphoma types, including classic Hodgkin lymphoma (cHL), some peripheral T-cell lymphomas (PTCL), and some cutaneous T-cell lymphomas. The antibody–drug conjugate brentuximab vedotin targets CD30-positive cells and has been evaluated for the treatment of various lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Prince, H. Miles, Hutchings, Martin, Domingo-Domenech, Eva, Eichenauer, Dennis A., Advani, Ranjana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807535/
https://www.ncbi.nlm.nih.gov/pubmed/36512081
http://dx.doi.org/10.1007/s00277-022-05054-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807535/
https://www.ncbi.nlm.nih.gov/pubmed/36512081
http://dx.doi.org/10.1007/s00277-022-05054-9

Ejemplares similares